论文部分内容阅读
Ｐ３是用人Ｔ细胞与小鼠Ｓｐ２／０骨髓瘤细胞融合而成的人鼠Ｔ－Ｂ细胞杂交瘤，其表面具有人Ｔ细胞Ｅ玫瑰花受体标志，我们将Ｐ３作为肿瘤疫苗进行了初步的抗肿瘤实验研究，结果表明：Ｐ３细胞在ＢＡＬＢ／ｃ小鼠体内失去了成瘤性。Ｐ３肿瘤疫苗有较好的治疗肿瘤的作用，实验组瘤重７４７±１８２ｍｇ，显著轻于对照组瘤重２７２５±９５２ｍｇ，Ｐ＜０．０００１。在肿瘤预防实验中，Ｐ３瘤苗存活期为：３１．６±６．８天，显著长于对照组的２４．０±２．１天，Ｐ＜０．０００１。用ＢＣＧ和ＩＬ－２可强化Ｐ３瘤苗的抗肿瘤效应，表现为Ｐ３＋ＢＣＧ＋ＩＬ－２组小鼠存活期显著延长，并有２／８的小鼠存活期大于６０天，且无瘤生长。
P3 is a human and mouse T-B cell hybridoma fused with mouse Sp2/0 myeloma cells. The surface has the human T-cell E rosette receptor marker. We performed P3 as a tumor vaccine initially. Anti-tumor experiments showed that P3 cells lost tumorigenicity in BALB/c mice. P3 tumor vaccine had a better therapeutic effect on tumors. The tumor weight in the experimental group was 747±182 mg, which was significantly lighter than that of the control group. The tumor weight was 2725±952 mg, P<0.0001. In the tumor prevention experiment, the survival period of P3 vaccine seedlings was 31.6±6.8 days, which was significantly longer than 24.0±2.1 days in the control group, P<0.0001. The anti-tumor effects of P3 tumor vaccines were enhanced by BCG and IL-2. The survival of mice in the P3+BCG+IL-2 group was significantly prolonged, and 2/8 of the mice survived longer than 60 days. No tumor growth was observed.